PE20091007A1 - Depsipeptidos ciclicos como moduladores de calicreina 7 - Google Patents

Depsipeptidos ciclicos como moduladores de calicreina 7

Info

Publication number
PE20091007A1
PE20091007A1 PE2008001396A PE2008001396A PE20091007A1 PE 20091007 A1 PE20091007 A1 PE 20091007A1 PE 2008001396 A PE2008001396 A PE 2008001396A PE 2008001396 A PE2008001396 A PE 2008001396A PE 20091007 A1 PE20091007 A1 PE 20091007A1
Authority
PE
Peru
Prior art keywords
ona
amino
calicrein
modulators
ahp
Prior art date
Application number
PE2008001396A
Other languages
English (en)
Inventor
Philipp Krastel
Brigitta-Maria Liechty
Josef Gottfried Meingassner
Esther Schmitt
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38805728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091007A1 publication Critical patent/PE20091007A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

REFERIDA A UN DEPSIPEPTIDO CICLICO DE FORMULA (I), DONDE SE FORMA UN ENLACE ESTER ENTRE UN GRUPO CARBOXILO DE A7 Y UN GRUPO HIDROXILO DE A2; X ES H O UN RESIDUO ARILO, CARBONILO O ACILO; A1 ES GLUTAMINA, ORNITINA, ACIDO GLUTAMICO O UN DERIVADO DE LOS MISMOS; A2 ES TREONINA O SERINA; A3 ES LEUCINA; A4 ES 3-AMINO-6-HIDROXI-PIPERIDIN-2-ONA (Ahp), 3-AMINO-3,4-DIHIDRO-1H-PIRIDIN-2-ONA (DEHIDRO-Ahp), 3-AMINO-PIPERIDIN-2-ONA, ENTRE OTROS; A5 ES ISOLEUCINA, FENILALANINA O VALINA; A6 ES TIROSINA, N-Me-TIROSINA O UN DERIVADO DE LAS MISMAS; A7 ES LEUCINA, ISOLEUCINA O VALINA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHOS DEPSIPEPTIDOS PRODUCIDOS POR MICROORGANISMOS CHONDROMYCES TALES COMO CHONDROMYCES CROCATUS, APICULATUS O ROBUSUTUS SON MODULADORES DE LA CALICREINA 7 Y SON UTILES EN EL TRATAMIENTO DEL CANCER, ENFERMEDADES INFLAMATORIAS, HIPERPROLIFERATIVAS, ENTRE OTRAS
PE2008001396A 2007-08-17 2008-08-15 Depsipeptidos ciclicos como moduladores de calicreina 7 PE20091007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114507 2007-08-17

Publications (1)

Publication Number Publication Date
PE20091007A1 true PE20091007A1 (es) 2009-08-14

Family

ID=38805728

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001396A PE20091007A1 (es) 2007-08-17 2008-08-15 Depsipeptidos ciclicos como moduladores de calicreina 7
PE2014000462A PE20141199A1 (es) 2007-08-17 2008-08-15 Depsipeptidos ciclicos como moduladores de calicreina 7

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000462A PE20141199A1 (es) 2007-08-17 2008-08-15 Depsipeptidos ciclicos como moduladores de calicreina 7

Country Status (30)

Country Link
US (2) US8178650B2 (es)
EP (1) EP2183273B1 (es)
JP (1) JP5520824B2 (es)
KR (2) KR20120123579A (es)
CN (1) CN103298827B (es)
AR (1) AR068343A1 (es)
AU (1) AU2008290567B2 (es)
BR (1) BRPI0815547B8 (es)
CA (1) CA2696570C (es)
CL (1) CL2008002394A1 (es)
CO (1) CO6260099A2 (es)
CR (1) CR11251A (es)
CU (2) CU23943B1 (es)
EA (1) EA017735B1 (es)
EC (1) ECSP109968A (es)
ES (1) ES2632392T3 (es)
GT (1) GT201000037A (es)
MA (1) MA31701B1 (es)
MX (1) MX2010001849A (es)
MY (1) MY151973A (es)
NZ (1) NZ583284A (es)
PE (2) PE20091007A1 (es)
PL (1) PL2183273T3 (es)
PT (1) PT2183273T (es)
SV (1) SV2010003485A (es)
TN (1) TN2010000074A1 (es)
TW (1) TW200922613A (es)
UA (1) UA98658C2 (es)
WO (1) WO2009024527A1 (es)
ZA (1) ZA201000776B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415305B2 (en) 2007-08-17 2013-04-09 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
UA98658C2 (uk) 2007-08-17 2012-06-11 Новартіс Аг Циклічні депсипептиди
CN102369211B (zh) * 2009-02-13 2015-04-29 诺华股份有限公司 编码非核糖体肽合酶的生物合成簇的核酸分子及其用途
US8680054B2 (en) * 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) * 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) * 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
EP3097084B1 (en) 2014-01-23 2020-09-30 Sixera Pharma AB New kallikrein 7 inhibitors
WO2015114144A1 (en) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of netherton syndrome
CN106029684A (zh) 2014-04-08 2016-10-12 诺华股份有限公司 用于生产大环缩酚酸肽和新中间体的新型缩醛类方法
KR101729848B1 (ko) 2015-06-30 2017-04-24 영남대학교 산학협력단 신규한 해양 바실러스속 균주, 이로부터 분리한 화합물 및 상기 화합물의 약제학적 용도
CN106518880B (zh) * 2015-11-04 2018-10-19 衡阳师范学院 激肽释放酶7小分子抑制剂及其制备方法与用途
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (de) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (de) * 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung
DE19828043A1 (de) 1998-06-24 1999-12-30 Bayer Ag Ektoparasitizide Mittel
JP2000154198A (ja) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd 環状デプシペプチドの固相合成方法及びその中間体
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
WO2004108139A2 (en) 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1716248A1 (en) * 2004-02-03 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US8415305B2 (en) 2007-08-17 2013-04-09 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
UA98658C2 (uk) 2007-08-17 2012-06-11 Новартіс Аг Циклічні депсипептиди
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US20120064013A1 (en) 2010-02-03 2012-03-15 David Marcos Foamable topical composition
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
BR112013018918A2 (pt) 2011-01-24 2016-10-04 Anterios Inc composições de nanopartículas
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates

Also Published As

Publication number Publication date
CN103298827B (zh) 2017-05-31
AU2008290567A1 (en) 2009-02-26
KR20100044893A (ko) 2010-04-30
US8178650B2 (en) 2012-05-15
BRPI0815547A2 (pt) 2015-02-10
BRPI0815547B1 (pt) 2020-09-15
CR11251A (es) 2010-03-08
KR20120123579A (ko) 2012-11-08
BRPI0815547B8 (pt) 2021-05-25
CL2008002394A1 (es) 2009-05-15
CU20130063A7 (es) 2013-06-28
ES2632392T3 (es) 2017-09-12
CA2696570C (en) 2020-12-29
CN103298827A (zh) 2013-09-11
SV2010003485A (es) 2011-03-23
JP2010536731A (ja) 2010-12-02
NZ583284A (en) 2012-04-27
MY151973A (en) 2014-07-31
ECSP109968A (es) 2010-03-31
CU23943B1 (es) 2013-09-27
AR068343A1 (es) 2009-11-11
US20120196790A1 (en) 2012-08-02
JP5520824B2 (ja) 2014-06-11
US9127044B2 (en) 2015-09-08
EA201000329A1 (ru) 2010-08-30
EP2183273B1 (en) 2017-04-05
TN2010000074A1 (en) 2011-09-26
TW200922613A (en) 2009-06-01
CA2696570A1 (en) 2009-02-26
US20090156472A1 (en) 2009-06-18
MX2010001849A (es) 2010-03-10
MA31701B1 (fr) 2010-09-01
ZA201000776B (en) 2010-10-27
WO2009024527A1 (en) 2009-02-26
CO6260099A2 (es) 2011-03-22
PL2183273T3 (pl) 2017-09-29
EA017735B1 (ru) 2013-02-28
PT2183273T (pt) 2017-05-22
EP2183273A1 (en) 2010-05-12
PE20141199A1 (es) 2014-09-24
AU2008290567B2 (en) 2011-05-12
GT201000037A (es) 2012-04-30
KR101227231B1 (ko) 2013-01-28
CU20100032A7 (es) 2011-10-05
UA98658C2 (uk) 2012-06-11

Similar Documents

Publication Publication Date Title
PE20091007A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
CL2004001602A1 (es) Compuestos no esteroidales derivados de propionanilida, moduladores del receptor androgenico con selectividad tisular (sarm); composicion farmaceutica; y uso en el tratamiento o prevencion de condiciones dependientes del receptor androgenico, como hi
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
CR20110204A (es) Moleculas de anticuerpo mejoradas
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
WO2010123946A3 (en) Silk fibroin hydrogels and uses thereof
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
CO6351689A2 (es) Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
CO6460762A2 (es) 5-alquinil-piridinas
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
BR112014000901A2 (pt) processo de separação
NZ594419A (en) Process for purifying guar

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed